Jury ' s Still Out on Trifluridine/Tipiracil Plus Bev in mCRC Jury ' s Still Out on Trifluridine/Tipiracil Plus Bev in mCRC

First-line trifluridine/tipiracil plus bevacizumab offered a slight survival benefit over capecitabine plus bevacizumab in patients with unresectable metastatic colorectal cancer in the TASCO1 trial.Medscape Medical News

Source: Medscape Hematology-Oncology Headlines - January 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news